Skip to main content

Table 3 Inhibitory potential of a variety of HIV-1 inhibitors towards WT and mutant virus strains containing the N674D mutation or a combination of glycan deletions in gp41

From: The role of N-glycans of HIV-1 gp41 in virus infectivity and susceptibility to the suppressive effects of carbohydrate-binding agents

  Nr HHA (nM) UDA (nM) AH (nM) 2G12 (nM) PRM-S ( μM) T-20 (nM) AMD3100 (nM)
WT   0.9 ± 0.2 25 ± 3 5.2 ± 1.0 1.1 ± 0.2 4.8 ± 0.4 340 ± 141 3.5 ± 0.6
N674D   1.9 ± 0.6 34 ± 10 2.1 ± 0.5 0.8 ± 0.2 4.7 ± 0.4 63 ± 20 3.3 ± 0.3
N611Q/N637Q #2 2.7 ± 0.4 63 ± 7 3.0 ± 0.7 0.5 ± 0.1 4.8 ± 0.4 49 ± 4 3.5 ± 0.3
N625Q/N637Q #4 1.4 ± 0.2 51 ± 6 3.8 ± 0.1 0.8 ± 0.2 5.3 ± 0.1 21 ± 2 3.3 ± 0.4
N625Q/N674Q #5 1.3 ± 0.3 30 ± 2 3.2 ± 0.3 0.9 ± 0.1 5.3 ± 0.1 57 ± 4 3.5 ± 0.1
N637Q/N674Q #6 1.6 ± 0.5 28 ± 10 4.3 ± 0.9 0.9 ± 0.0 5.3 ± 0.1 48 ± 24 3.6 ± 0.3
N625Q/N637Q/N674Q #B 2.1 ± 0.1 35 ± 6 3.2 ± 0.7 0.5 ± 0.1 5.0 ± 0.1 20 ± 2 3.5 ± 0.3
N611Q/N637Q/N674Q #C 2.8 ± 0.6 52 ± 7 3.6 ± 0.4 0.6 ± 0.0 5.3 ± 0.2 56 ± 10 3.3 ± 0.2
  1. Values represent the EC50’s (50% effective concentration) of the test compounds expressed in nM or μM.
  2. Data are the means ± SEM of at least 3 independent experiments.